These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3178488)

  • 1. Protective capacity of polyclonal and monoclonal antibodies directed against endotoxin during experimental sepsis.
    Dunn DL; Priest BP; Condie RM
    Arch Surg; 1988 Nov; 123(11):1389-93. PubMed ID: 3178488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of type-specific and cross-reactive murine monoclonal antibodies directed against endotoxin during experimental sepsis.
    Dunn DL; Bogard WC; Cerra FB
    Surgery; 1985 Aug; 98(2):283-90. PubMed ID: 3895540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of experimental gram-negative bacterial sepsis with murine monoclonal antibodies directed against lipopolysaccharide.
    Priest BP; Brinson DN; Schroeder DA; Dunn DL
    Surgery; 1989 Aug; 106(2):147-54; discussion 154-5. PubMed ID: 2763023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and potential use of antibody directed against lipopolysaccharide for the treatment of gram-negative bacterial sepsis.
    Dunn DL
    J Trauma; 1990 Dec; 30(12 Suppl):S100-6. PubMed ID: 2254968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody immunotherapy of gram-negative bacterial sepsis in an immunosuppressed animal model.
    Dunn DL
    Transplantation; 1988 Feb; 45(2):424-9. PubMed ID: 3278438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of gram-negative bacterial sepsis. A single murine monoclonal antibody provides cross-genera protection.
    Dunn DL; Ewald DC; Chandan N; Cerra FB
    Arch Surg; 1986 Jan; 121(1):58-62. PubMed ID: 3942500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of endotoxin contamination in the evaluation of antibodies to lipopolysaccharides in a murine model of gram-negative sepsis.
    Chong KT; Huston M
    J Infect Dis; 1987 Nov; 156(5):713-9. PubMed ID: 3309071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticore endotoxin F(ab')2 equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial sepsis.
    Dunn DL; Mach PA; Condie RM; Cerra FB
    Surgery; 1984 Aug; 96(2):440-6. PubMed ID: 6379963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-endotoxin monoclonal antibodies inhibit secretion of tumor necrosis factor-alpha by two distinct mechanisms.
    Burd RS; Battafarano RJ; Cody CS; Farber MS; Ratz CA; Dunn DL
    Ann Surg; 1993 Sep; 218(3):250-9; discussion 259-61. PubMed ID: 8373268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effects of polyclonal sera and of monoclonal antibodies active to Salmonella minnesota Re595 lipopolysaccharide during experimental endotoxemia.
    Nys M; Cloes JM; Demonty J; Joassin L
    J Infect Dis; 1990 Nov; 162(5):1087-95. PubMed ID: 1700024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective anti-lipopolysaccharide monoclonal antibodies inhibit tumor necrosis factor production.
    Cody CS; Burd RS; Mayoral JL; Dunn DL
    J Surg Res; 1992 Apr; 52(4):314-9. PubMed ID: 1593869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity.
    Oishi K; Koles NL; Guelde G; Pollack M
    J Infect Dis; 1992 Jan; 165(1):34-45. PubMed ID: 1727896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with antibodies that mimic LPS protects against gram negative bacterial sepsis.
    Klaerner HG; Dahlberg PS; Acton RD; Battafarano RJ; Uknis ME; Johnston JW; Dunn DL
    J Surg Res; 1997 May; 69(2):249-54. PubMed ID: 9224390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of protection by two endotoxin-neutralizing IgM monoclonal antibodies in different peritonitis models.
    Hustinx WN; Benaissa-Trouw BJ; Harmsen T; Klein S; Verhoef J; Hoepelman AI; Kraaijeveld K
    J Antimicrob Chemother; 1997 Oct; 40(4):567-72. PubMed ID: 9372427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to lipopolysaccharide.
    Poxton IR
    J Immunol Methods; 1995 Oct; 186(1):1-15. PubMed ID: 7561138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to lipopolysaccharide.
    Fink MP
    Crit Care Med; 1993 Feb; 21(2 Suppl):S32-9. PubMed ID: 8428494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specificity and function of monoclonal antibodies reactive with discrete structural elements of bacterial lipopolysaccharide.
    Pollack M; Oishi K; Chia J; Evans M; Guelde G; Koles N
    Adv Exp Med Biol; 1990; 256():331-40. PubMed ID: 1691578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies.
    Teng NN; Kaplan HS; Hebert JM; Moore C; Douglas H; Wunderlich A; Braude AI
    Proc Natl Acad Sci U S A; 1985 Mar; 82(6):1790-4. PubMed ID: 3856860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissociation between Limulus neutralisation and in vivo protection in monoclonal antibodies directed against endotoxin core structures.
    McConnell JS; Appelmelk BJ; Cohen J
    Microb Pathog; 1990 Jul; 9(1):55-9. PubMed ID: 2077344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.